<DOC>
	<DOCNO>NCT01307800</DOCNO>
	<brief_summary>The purpose study determine whether least 1 dose level LY2140023 give acutely ill patient schizophrenia demonstrate significantly great efficacy compare placebo .</brief_summary>
	<brief_title>A Study LY2140023 Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Diagnosis schizophrenia define Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision DSMIVTR ; confirm Structured Clinical Interview DSMIVTR ( SCID ) Non pregnant female patient agree use acceptable birth control Participants must consider moderately ill opinion investigator Patients modification antipsychotic medication initiation antipsychotic medication acutely indicated opinion investigator Willing participate minimum 2 week inpatient hospitalization . One year history Schizophrenia prior enter study At study entry patient history antipsychotic treatment must lifetime history least one hospitalization treatment schizophrenia , include hospitalization require study . Patients never take antipsychotic treatment may enter study even without history hospitalization At study entry patient history antipsychotic treatment must history least one episode illness exacerbation require intensification treatment intervention care last 2 year , include present episode illness . Patients never take antipsychotic treatment may enter study without past history illness exacerbation intensification treatment last 2 year At study entry patient must experience exacerbation illness within 2 week prior enter study , lead intensification psychiatric care opinion investigator . If exacerbation occur patient presently hospitalize , patient must hospitalize longer 60 day entry study Patients must consider reliable level understanding sufficient perform test examination require protocol , willing perform study procedures Patients history inadequate clinical response antipsychotic treatment schizophrenia Diagnosis substance dependence substance abuse within 6 month study entry Diagnosis substanceinduced psychosis within 7 day study entry Currently enrol , discontinue within 6 month clinical trial involve investigational product unapproved use drug device Participated clinical trial pharmacological treatment intervention receive studyrelated medication 6 month prior study entry Previously complete withdrawn study , study investigate LY2140023 predecessor molecule glutamatergic activity Treatment clozapine dose great 200 mg daily within 12 month prior enter study , receive clozapine month study entry Patients currently receive treatment ( within 1 dose interval , minimum 4 week , prior enter study ) depot formulation antipsychotic medication Patients currently suicidal Females pregnant , nursing , intend become pregnant within 30 day complete study Patients uncorrected narrowangle glaucoma , uncontrolled diabetes , certain disease liver , renal insufficiency , uncontrolled thyroid condition serious unstable illness Have history one seizures Electroconvulsive therapy ( ECT ) within 3 month enter study ECT time study History low white blood cell count Medical history Human Immunodeficiency Virus positive ( HIV+ ) status . Higher normal blood prolactin level Abnormal electrocardiogram result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>